Covid 19 Research using Clinical Trials (Home Page)
ACE inhibitorWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug842 | Thiazide or Thiazide-like diuretics Wiki | 0.71 |
| drug50 | Angiotensin receptor blocker Wiki | 0.71 |
| drug947 | convalescent plasma from recovered COVID 19 donor Wiki | 0.71 |
| drug167 | Calcium Channel Blockers Wiki | 0.71 |
Correlated MeSH Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D006973 | Hypertension NIH | 0.32 |
| D012141 | Respiratory Tract Infections NIH | 0.18 |
| D018352 | Coronavirus Infections NIH | 0.04 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 2 clinical trials
Clinical Trials
1 The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? An Analysis Using UK Based Electronic Health Records of 5.6 Million Individuals.
The study use UK based linked electronic health records from the Clinical Research Datalink (CALIBER) of 5.6 million individuals to conduct a matched case-control study to investigate the incidence of influenza in individuals prescribed ACEI compared to those not prescribed ACEI.
NCT04322786 Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom Drug: ACE inhibitor MeSH:Respiratory Tract Infections
HPO:Respiratory tract infection
Primary Outcomes
Measure: Incidence of influenza Time: Jan 1st 1998 - May 31st 2016
2 The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial
Primary Outcomes
Measure: Incidence of influenza Time: Jan 1st 1998 - May 31st 2016Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require the angiotensin-converting enzyme 2 (ACE-2) receptor for uptake into the human body, there have been questions about whether medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications. One such group of medications are anti-hypertensives that block the renin-angiotensin system, including both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB). Both ACEi and ARB are widely used for the treatment of hypertension. Early reports from China and Italy suggest that many of those who die from COVID-19 have a coexisting history of hypertension. Consequently, there have been questions raised as to whether these 2 types of blood pressure medication might increase the risk of death among patients with COVID-19. However, it is well known that the prevalence of hypertension increases linearly with age. Therefore, it is possible that the high prevalence of hypertension and ACEi/ARB use among persons who die from COVID-19 is simply confounded by age (older people are at risk of both a history of hypertension and dying from COVID-19). Whether these commonly prescribed blood pressure medications increase the risk of COVID-19 or not remains unanswered. Statements from professional cardiology societies on both sides of the Atlantic have called for urgent research into this question. Our study aims to randomize patients with primary (essential) hypertension who are already taking ACEi/ARB to either switch to an alternative BP medication or continue with the ACEi/ARB that they have already been prescribed. Adults with compelling indications for ACEi/ARB will not be enrolled.
NCT04330300 Hypertension COVID-19 Drug: Thiazide or Thiazide-like diuretics Drug: Calcium Channel Blockers Drug: ACE inhibitor Drug: Angiotensin receptor blocker MeSH:Coronavirus Infections Hypertension
HPO:Hypertension
Primary Outcomes
Description: Time from randomization to the first occurrence of any of the clinical events above
Measure: Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV) Time: 12 months
Secondary Outcomes
Description: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who die Time: 12 months
Description: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who require intubation in intensive care unit (ICU) Time: 12 months
Description: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV) Time: 12 months
Description: Time from randomization to the first occurrence of above
Measure: Number of SARS-CoV-2 positive participants Time: 12 months
Measure: Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization Time: 12 months
Description: Performed in a random sub-sample of the cohort (both study arms)
Measure: 24 hour mean systolic BP (mmHg) on ambulatory BP monitoring Time: 12 months
Description: Time from randomization to the first occurrence of above
Measure: All-cause mortality Time: 12 months
Related HPO nodes (Using clinical trials)
HP:0000822: Hypertension
Genes 410
GPC3 MPL PRKAR1A ABCG8 ND1 CYP11B1 TRNS1 B2M MMP2 BRCA2 SDCCAG8 HMBS LYZ PKD1 C8ORF37 BSCL2 WT1 SCNN1B SLC25A11 COX2 CEP19 TRNQ YY1AP1 ECE1 WT1 KCNJ5 ENPP1 FN1 PDE11A HGD SLC25A11 HSD11B2 MFAP5 GUCY1A1 DYRK1B SPRY2 SLC2A10 SMAD6 COX3 SCNN1G SCNN1B LARS2 FOXF1 NPHP4 TRNL1 TMEM67 IL12B HIRA TRIM28 MLXIPL CDH23 CLIP2 HLA-B TRNF POU6F2 NFU1 SDHC CEP290 ENPP1 EDA CYTB SDCCAG8 HLA-DPB1 SCNN1A NKX2-5 COL5A1 LEMD3 YY1AP1 TBL2 ALMS1 NOTCH3 CLCN2 ARVCF SEC24C CFH FH TGFB2 TMEM127 ARMC5 AIP SDHA JMJD1C COX1 ND5 COMT NF1 CACNA1D TGFBR1 REST LDLRAP1 GTF2I PDE3A TNFRSF11B MAT2A HSD11B2 TRNH CORIN SERPINA6 BBS10 AIP MAFB FOXE3 SCN2B SMAD4 CYP11B1 TRNK SLC52A3 TRNL1 CYP17A1 GBA SDHB BBS1 HBB CCR6 XPNPEP3 ERCC4 VHL BBS7 GP1BB TRNE OSGEP PPARG NOS3 TRPC6 HMBS JAK2 VHL KRT18 TRNS1 WT1 NPHP1 SDHD INVS KCTD1 OFD1 USP8 FIG4 TRIM28 LRIG2 PCSK9 SDHB SCNN1G CCN2 COL1A1 TRNL1 WT1 PTPN22 LDLR PRKAR1A COX1 VHL TRNC COQ7 LEMD3 PRKACA MKKS BBS5 SLC52A2 SDHD TRNW COX3 RREB1 GPR101 SMAD3 INVS KIF1B DNAJB11 COX2 APOA1 RET ARHGAP31 KCNJ5 WT1 ND5 GDNF CUL3 GLA FLT1 ACVRL1 TNFRSF11A VHL GNAS PRTN3 COL3A1 ABCC6 XYLT1 CYP11B1 ADAMTSL4 FGA C3 COL5A2 BBS9 ERCC6 KCNJ5 FBN1 APOB BAZ1B PAM16 POU3F4 TMEM70 ND4 STOX1 GNAS RFC2 TGFBR2 CALR IQCB1 CYP21A2 MMP14 SLC37A4 ALX4 TRNQ TBX1 THPO GTF2IRD1 GATA5 ND6 FN1 RPGRIP1L CFB ANGPTL6 RET XYLT2 VANGL1 NR3C1 PDE11A NR3C2 POR TRNK BMPR2 MGP TRNV SUGCT RET MYH11 PRKAR1A MDH2 FMO3 KLHL3 WNK4 TMEM237 LZTFL1 TRNK IRF5 STAT1 NSMCE2 MUC1 COL4A4 HLA-DPA1 GLA IDUA NOTCH2 TRNW CC2D2A SCNN1A NR3C1 CPOX USP8 BBS2 ELN CYP11B2 SMARCAL1 LMX1B BNC2 TRIM32 MAX MKS1 PKD2 LRP6 PRKACA COL3A1 SDHD NPHP1 MAX PRKG1 MYLK HLA-DRB1 DIS3L2 CFI LMX1B ACAT1 ELN EGFR ND6 ELP1 ELN SLC37A4 PPARG CEP164 LMNA PLIN1 DLST TP53 TRNF SMAD4 LOX UFD1 FMR1 SDHB NOTCH1 SMAD4 BBS12 IFT172 ABCG5 MYMK CFHR1 TRIP13 SLC2A10 GJA1 WDPCP FUZ CYP17A1 TRNS2 WDR35 MYH7 SDHAF2 LMNA NPHP3 GUCY1A1 EXT2 HPSE2 OFD1 LMNA FGFR2 MEF2A PLIN1 COL4A3 CEP290 ACTA2 KIF1B CD2AP TGFB3 FBN1 TRNS2 SH2B3 COL4A5 NOD2 SDHC PDE3A G6PC THBD FBN1 CAV1 TTC8 ALMS1 ITGA8 LMNA GANAB LIMK1 BBIP1 CTLA4 BANF1 CCDC28B CFHR3 FBN1 H19 CACNA1H ARMC5 AIP CCND1 ADA2 ARL6 EDA2R CBS SH2B3 TET2 CACNA1D ADA2 ND1 VAC14 IFT27 PDE8B CYP11B1 TRAF3IP1 CDH23 BBS1 TMEM127 COL4A3 GNAS ELP1 ACTA2 NPHP1 MTTP WNK1 WDR19 ZMPSTE24 CD46 GCH1 KCTD1 ADA2 ABCB6 ACTN4 NFIX ENG TGFBR3 ABCC6 WRN LMNA BBS4 PKHD1 FGFR2 MC4R ERCC8 KIF1B KRT8 TBX1 JAK2 PHF21A MLX ABCC6 HP:0011947: Respiratory tract infection
Genes 633
TIMM8A DNAH9 SIK1 ARID1B NFKBIA GTF2H5 IER3IP1 TNFRSF11A GUSB TBC1D24 BIRC3 IL17RA SPAG1 MSN WDR34 CTSC GAS2L2 NIPBL BTK NFKB1 FCGR3A CRELD1 IGLL1 RNF168 ZBTB24 STAT3 RFX5 TAF1 MKRN3 PLEC CFTR IRAK4 COLQ DNAAF4 TCTN3 MYO9A TGFB1 LEPR SLC18A3 TAP2 LAMA2 PEPD NGLY1 CFAP300 WAS DNAI1 TBCD DNAAF2 SELENON IL2RG IRAK4 ARMC4 SOX4 RSPH1 IFNGR1 GLI3 ALOX12B DNAL1 ZMYND10 UNG NRAS RFXAP IL2RB NKX2-1 RSPH9 PLOD1 SPINK5 SCNN1B GBA GAS8 CFAP298 CLCA4 GNPTAB LEP CLIP2 CCDC65 CD3G FCN3 CYBA SMN1 TRIP4 EP300 USB1 UBB DOCK8 LAMTOR2 TBC1D24 NECTIN1 SAMD9 SCNN1G CCNO CIITA MUC5B HLA-DPB1 DNAAF1 LCK ICOS NPM1 SPAG1 CCDC40 TRAIP CARD11 RSPH4A TBL2 ASAH1 PTPRC ALMS1 RUNX2 DNAAF4 NOTCH3 SH3KBP1 SNORD115-1 DNAI1 BACH2 RAG2 TSC1 TNFRSF13C IDUA IL2RG DNAAF6 GALNS IDUA SLC25A22 FUCA1 B2M SFTPC FLI1 CD3E MGP CD8A ELANE SULT2B1 TCF3 SLC29A3 RELB TPM2 CCDC103 ACTA1 HELLS FCGR2A LAMB2 SLC5A7 SPEF2 AGA SDR9C7 PYROXD1 CLEC7A HERC2 KRAS SMPD1 SOX11 CD247 MESP2 DDR2 GTF2I BLNK KIAA0586 BLNK FOXP1 SMARCA4 EDARADD SGCG MYSM1 ARID1A GNS CD79B MPLKIP LYST NPAP1 NCF1 CYP4F22 SRP54 TPP2 RNU4ATAC TRIP11 NGLY1 LRBA DNMT3B P4HTM SELENON STX1A TRPS1 COL13A1 TNFRSF13B DNAAF5 VPS13A CD81 INPPL1 CARMIL2 TAP1 NOTCH2 MESP2 GATA2 SNX10 CSF2RB SDCCAG8 JAK3 TBCE DOCK8 SHROOM4 RTEL1 OSTM1 CCDC151 LETM1 SMPD1 IL21 DNAJB13 JAK3 RNF125 INSR STK36 SCN10A IL7R MYH3 POLA1 CD19 CR2 ARID1B CD3D RSPH3 TAPBP CYBB DRC1 VAMP1 ADNP DCLRE1C PTPN22 NDN SGSH ARSB LRRC56 LRRC6 SP110 CCDC40 SLC25A1 ASAH1 PCGF2 BTK CCBE1 COL6A1 GATA6 PGM3 COG4 PSAP SLC46A1 SCN9A IKBKB CFB GAS2L2 TGFB1 PEPD SMARCC2 RNU4ATAC MYL2 SCN11A COL6A2 POLR3A GTF2E2 TSC2 WRAP53 ITGA3 CFI SCNN1B BTK CCDC22 DNAI2 CFTR ZAP70 DCTN4 CD79B RYR1 ADAMTS3 CD81 PLG SYT2 USP9X DKC1 KIF1A PRPS1 ELANE AFF4 ALB NME8 TNFRSF13C MAP3K20 TNFSF12 TIRAP STAT3 CCDC114 ADA SMARCE1 DSG1 PIK3R1 RPGR CREBBP HACD1 PRTN3 NFE2L2 DPM2 FLNA RMRP DNAH11 ERF EPM2A HYDIN G6PC3 ATM GAS8 SNORD116-1 DNAH11 NFKB2 EPG5 BCL10 DPF2 BAZ1B ERCC2 AK2 EHMT1 MS4A1 DNAAF3 CCDC151 LIG4 NFKB2 FBLN5 ZMYND10 ATP6V0A2 IL17RA TARS1 NXN COL6A3 TCIRG1 RFC2 WASHC5 WIPF1 GATA4 NOP10 RFXANK RSPH4A HLA-B SLC52A3 NME8 NHP2 CXCR4 GSN PCNT TNFRSF13B LEP IL17RC AGRN CORO1A CCDC65 RPGR NADK2 CD55 GTF2IRD1 IL17F ALG12 COL11A2 NHLRC1 ABCA12 LTBP3 SCNN1B ABCA12 NSD2 TECPR2 MANBA PARN GFI1 EPG5 NBN FLNA RNF113A CCDC39 PMM2 SCNN1A ICOS RFXANK TNFSF12 PWRN1 CARD11 SFTPC MGP USB1 OFD1 JAGN1 LRRC6 TYK2 IL21R FMO3 CFTR AGA PLP1 STAT1 NR2F2 CYBC1 SLC35A1 HLA-DPA1 RIPK1 DNAAF1 ORC6 RAG2 HPS6 CACNA1C GMNN IDUA RYR1 CFAP298 KIAA0556 TNFRSF13B AICDA KDM6A CLCN7 PANK2 SAMD9L RANBP2 ROR2 ELN CIITA TPM3 RSPH3 ADA DNAAF2 KMT2D ZNF341 GBA TNFRSF1A IL7R LEPR NAGLU RAG2 COG4 SCNN1A IGHM DLL3 TRAF3IP2 CSF2RA LAMTOR2 BLM NSMCE3 UMPS PGM3 RFX5 GRHL3 EGFR ELP1 PNP LIPN DNAH5 HGSNAT SETBP1 ECM1 TTC25 CR2 ADA MASP2 SFTPA2 AP3D1 MBTPS2 RAC1 TTC25 KAT6B ZAP70 IFIH1 ALPL IGHM SCNN1G DNAAF5 RAG2 NBN FAT4 SNRPN CD19 TGM1 ACADVL TNFSF11 CYBB PTPN22 PEX13 TK2 CACNA1B GAA PRKDC ARMC4 ALOXE3 CR2 CYBA RAG1 NCF1 SNAP25 CDCA7 IPW CXCR4 TERC RAG1 CD19 CD3E CD79A DNAH5 TFRC MCM4 FOXP3 IRF8 CFAP221 CTC1 LYST DNAI2 KCNJ6 EXOSC9 CD3D CRKL RYR1 CCDC114 PLG DCLRE1C SLC25A24 DCLRE1C LRRC8A ICOS TGFB1 CTLA4 XIAP IL7R IKBKG VPS33A FOXJ1 NELFA IL2RG CASP8 RAG1 CHAT IGLL1 CFAP410 CCNO ALMS1 NCF2 UNC119 GLB1 CHRM3 RSPH1 TNFRSF13C ERCC3 LIMK1 CTLA4 CD79A RAG1 SLC26A2 STAT1 DNAH1 RSPH9 CFTR NCF2 WAS MECP2 CCDC103 IL2RA SLC12A6 ACTA1 IKBKB ATM DNAAF3 LRRC56 RAB3GAP2 PIGN MAGEL2 IKZF1 PRKCD ACP5 CHAMP1 SLC35C1 MKRN3-AS1 HYDIN SH2D1A MTHFD1 SMARCB1 NCF4 RAG1 XIAP MAPK1 PIK3R1 TERT PWAR1 CHD7 IGH OCRL MS4A1 DNAAF6 PIK3R1 SMARCD2 CCDC39 TBX6 UBE2A STING1 NKX2-1 ELP1 OFD1 COL13A1 ARID2 ZBTB24 TINF2 MYO5A WDR19 GNPTAB COL11A2 NFIX RAG2 SCNN1A RFXAP PLCG2 USP9X NFKB1 NIPAL4 NCF4 ZNHIT3 MALT1 SCNN1G IL2RG BCR POLE TCIRG1 INPPL1 TBC1D23 GBA DNAJB13 GUSB PIK3CD ITGA7 CSPP1 SMN1 TERT DNMT3B NFKB2 MCIDAS DCLRE1C Protein Mutations 1
H275Y SNP 0
Primary Outcomes
Description: Time from randomization to the first occurrence of any of the clinical events above
Measure: Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV) Time: 12 monthsSecondary Outcomes
Description: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who die Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who require intubation in intensive care unit (ICU) Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV) Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: Number of SARS-CoV-2 positive participants Time: 12 monthsMeasure: Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization Time: 12 months
Description: Performed in a random sub-sample of the cohort (both study arms)
Measure: 24 hour mean systolic BP (mmHg) on ambulatory BP monitoring Time: 12 monthsDescription: Time from randomization to the first occurrence of above
Measure: All-cause mortality Time: 12 months